Toll-like receptor-7 and -8 modulatory 1
The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides TLR7 agonists and TLR7/TLR8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof. Derivatives of the imidazoquinoline derived compounds also include dendrimers and dimers of the imidazoquinoline derived compounds, and methods of making and using the dendrimeic and dimeric imidazoquinoline derived compounds. The present disclosure also provides dual TLR2/TLR7 hybrid agonists that include imidazoquinoline derived compounds of the present disclosure.
1. An imidazoquinoline derived compound of Formula I or pharmaceutically acceptable salt thereof, wherein
Formula I has the structure:
wherein, R is selected from the group consisting of: —NH(R 5 ) and isothiocyanate;
R 5 is selected from the group consisting of hydrogen, acetyl, —CO-tert-Bu (-Boc), —CO—(CH 2 ) x —R 6 , C 1 -C 16 alkyl, —CO-4-(phenylboronic acid), —C(S)—NH—(CH 2 ) x —NH—(CH 2 ) x —NH—(CH 2 ) x —NH 2 ,
a reporter moiety, a tissue-specific moiety, a peptide antigen moiety, a protein antigen moiety, a polysaccharide antigen moiety, and a TLR2 agonist moiety;
R 6 is selected from the group consisting of hydrogen, alkyne, azido, carboxylic acid, and —CONH—(CH 2 ) x —O—(CH 2 ) x —O—(CH 2 ) x —O—(CH 2 ) x —R 7 ;
R 7 is selected from the group consisting of amino, isothiocyanate, and —NH—CO—(CH 2 ) x —CO 2 H;
R 8 is selected from a peptide antigen moiety or a protein antigen moiety; and
x is any integer from 1 to 10.
2. The imidazoquinoline derived compound of claim 1 , wherein the compound is chosen from the compound 1-(4-(Aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine or pharmaceutically acceptable salts thereof.
3. The imidazoquinoline derived compound of claim 1 , wherein the compound is chosen from: tert-butyl4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzylcarbamate, 1-(4-(Aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine, 2-Butyl-1-(4-(isothiocyanatomethyl)benzyl)-1H-imidazo[4,5-c]quinolin-4-amine, 1-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)phenyl)-3,7,23-trioxo-12,15,18-trioxa-2,8,22-triazaheptacosan-27-oic acid, 5-((4((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)amino)-5-oxopentanoic acid, N 1 -(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-N 5 -(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)glutaramide (14), N 1 -(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-N 5 -(3-(2-(2-(3-isothiocyanatopropoxy)ethoxy)ethoxy)propyl)glutaramide, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)palmitamide, 2-butyl-1-(4-((hexadecylamino)methyl)benzyl)-1H-imidazo[4,5-c]quinolin-4-amine, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-2-azidoacetamide, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)pent-4-ynamide, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamide, (4(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)carbamoyl)phenyl)boronic acid, 1-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-3-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)thiourea, 2-(3-(4-((4-Amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)thioureido)-6-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid, N-(9-(4-(3-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzypthioureido)-2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene)-N-ethylethanaminium, 5-(((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)phenoxy)acetyl)amino)pentylamine, hydrochloride conjugate of 2-Butyl-1-(4-(isothiocyanatomethyl)benzyl)-1H-imidazo[4,5-c]quinolin-4-amine, Methyl 1-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)phenyl)-6,9-dioxo-3-thioxo-2,4,7,10-tetraazadodecan-12-oate,
(2R)-methyl 2-amino-5-((2S)-3-(1-(3-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzylamino)-3-oxopropyl)-2,5-dioxopyrrolidin-3-ylthio)-1-(2-methoxy-2-oxoethylamino)-1-oxopropan-2-ylamino)-5-oxopentanoate, compound 31, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-N-((2R,3S,4R)-2,3,4,5,6--pentahydroxyhexyl)acetamide, 5-((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl) amino)-2-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-5-oxopentanoic acid, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide, 4-(((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzypamino)methyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol,
or pharmaceutically acceptable salts thereof.
4. The imidazoquinoline derived compound of claim 1 , wherein the compound is capable of activating Toll-like receptor (TLR) 7.
5. The imidazoquinoline derived compound of claim 4 , wherein the compound is chosen from tert-butyl 3-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzylcarbamate, tert-butyl 4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzylcarbamate, 1-(3-(Aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine, 1-(4-(Aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine, 2-Butyl-1-(4-(isothiocyanatomethyl)benzyl)-1H-imidazo[4,5-c]quinolin-4-amine, 1-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)phenyl)-3,7,23-trioxo-12,15,18-trioxa-2,8,22-triazaheptacosan-27-oic acid, 5-((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)amino)-5-oxopentanoic acid, N 1 -(4((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-N 5 -(3(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)glutaramide, N 1 -(4((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-N 5 -(3-(2-(2-(3-isothiocyanatopropoxy)ethoxy)ethoxy)propyl)glutaramide, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)palmitamide, 2-butyl-1-(4-((hexadecylamino)methyl)benzyl)-1H-imidazo[4,5-c]quinolin-4-amine, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]-quinolin-1-yl)methyl)benzyl)-2-azidoacetamide, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)pent-4-ynamide, N-(4-((4-amino-2-butyl-1H-imidazo[4,5- c]quinolin-1-yl)methyl) benzyl)-3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamide, (4-((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)carbamoyl)phenyl)boronic acid, 1-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-3-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)thiourea, 2-(3-(4-((4-Amino-2-butyl-1H-imidazo [4,5-c]quinolin-1-yl)methyl)benzyl)thioureido)-6-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid, N-(9-(4-(3-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)thioureido)-2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene)-N-ethylethanaminium, 5-(((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)phenoxy)acetyl)amino)pentylamine, hydrochloride conjugate of 2-Butyl-1-(4-(isothiocyanatomethyl)benzyl)-1H-imidazo[4,5-c]quinolin-4-amine, (2R)-methyl 2-amino-5-((2S)-3-(1-(3-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzylamino)-3-oxopropyl)-2,5-dioxopyrrolidin-3-ylthio)-1-(2-methoxy-2-oxoethylamino)-1-oxopropan-2-ylamino)-5-oxopentanoate,
N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-N-((2R,3S,4R)-2,3,4,5,6-pentahydroxyhexyl)acetamide, 5-((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl) amino)-2-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-5-oxopentanoic acid, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide, 4-(((4((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)amino)methyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol,
or pharmaceutically acceptable salts thereof.
6. The imidazoquinoline derived compound of claim 1 , wherein the compound is capable of activating TLR7 and TLR8.
7. The imidazoquinoline derived compound of claim 6 , wherein the compound is chosen from 1-(3-(Aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine, 1-(4-(Aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)pent-4-ynamide, 5-((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl) amino)-2-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-5-oxopentanoic acid, 4-(((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)amino)methyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol, or pharmaceutically acceptable salts thereof.
8. The imidazoquinoline derived compound of claim 1 , wherein the compound of Formula I is chosen from an isothiocyanate derivative of Formula I and a maleimide derivative of Formula I.
9. The imidazoquinoline derived compound of claim 1 , wherein R 5 comprises a reporter moiety comprising a reporter molecule chosen from a fluorescent molecule, an MRI agent, or a combination thereof.
10. The imidazoquinoline derived compound of claim 9 , wherein the compound is chosen from compounds 2-(3-(4-((4-Amino-2-butyl-1H-imidazo [4,5-c]quinolin-1-yl)methyl)benzyl)thioureido)-6-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid, N-(9-(4-(3-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)thioureido)-2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene)-N-ethylethanaminium, 5-(((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3--yl)phenoxy)acetyl)amino)pentylamine, hydrochloride conjugate of 2-Butyl-1-(4-(isothiocyanatomethyl)benzyl)-1H-imidazo[4,5-c]quinolin-4-amine, or pharmaceutically acceptable salts thereof.
11. The imidazoquinoline derived compound of claim 9 , wherein the reporter molecule is selected from the group consisting of: fluorescein, rhodamine B, bora-diazaindacene dye, 5-(((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)phenoxy)acetyl)amino)pentylamine, hydrochloride, and biotin.
12. The imidazoquinoline derived compound of claim 1 , wherein R 5 comprises an antigen moiety chosen from a peptide antigen moiety, a protein antigen moiety, or a polysaccharide antigen moiety, and wherein the imidazoquinoline derived compound is capable of activating TLR7.
13. The imidazoquinoline derived compound of claim 12 , wherein the protein antigen moiety comprises α-lactalbumin.
14. The imidazoquinoline derived compound of claim 12 , wherein the polysaccharide antigen moiety comprises maltoheptaose.
15. The imidazoquinoline derived compound of claim 1 , wherein R 5 comprises a tissue-specific moiety including a tissue-specific agent.
16. The imidazoquinoline derived compound of claim 15 , wherein the tissue-specific agent is chosen from galactose, folic acid, biotin, or pyridoxal.
17. The imidazoquinoline derived compound of claim 14 , wherein the compound is chosen from compounds N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-N-((2R,3S,4R)-2,3,4,5,6-pentahydroxyhexyl)acetamide, 5-((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl) amino)-2-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-5-oxopentanoic acid, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide, 4-(((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)amino)methyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol, or pharmaceutically acceptable salts thereof.
18. The imidazoquinoline derived compound of claim 1 , wherein R 5 comprises a TLR2 agonist moiety including a TLR2 agonist, and wherein the imidazoquinoline derived compound is capable of dual activation of TLR2 and TLR7.
19. The imidazoquinoline derived compound of claim 18 , wherein the TLR2 agonist is a S[2,3-bis(palmitoyloxy)-(2RS)-propyl]-R-cysteinyl-S-serine (PAM(2)CS) compound.
20. The imidazoquinoline derived compound of claim 18 , wherein the compound is chosen from compounds
or pharmaceutically acceptable salts thereof.
21. An imidazoquinoline derived compound comprising a dimer or a dendrimer of a compound of Formula I, a compound of Formula II or pharmaceutically acceptable salts thereof, wherein
wherein, R 1 and R 3 are each independently selected from the group consisting of hydrogen, halogen, nitro, —NH 2 , azido, hydroxyl, —CF 3 ,carboxylic acid and —CO 2 R 2 ;
R 2 is a C 2 -C 5 alkyl, and
R for Formula I and R 4 for Formula II are each independently selected from the group consisting of: —NH(R 5 ) and isothiocyanate;
R 5 is selected from the group consisting of hydrogen, acetyl, —CO-tert-Bu (-Boc), —CO—(CH 2 ) x —R 6 , C 1 -C 16 alkyl, —CO-4-(phenylboronic acid), —C(S)—NH—(CH 2 ) x —NH—(CH 2 ) x —NH—(CH 2 ) x —NH 2 ,
a reporter moiety, a tissue-specific moiety, a peptide antigen moiety, a protein antigen moiety, a polysaccharide antigen moiety, and a TLR2 agonist moiety;
R 6 is selected from the group consisting of hydrogen, alkyne, azido, carboxylic acid, and —CONH—(CH 2 ) x —O—(CH 2 ) x —O—(CH 2 ) x —O—(CH 2 ) X —R 7 ;
R 7 is selected from the group consisting of amino, isothiocyanate, and —NH—CO—(CH 2 ) x —CO 2 H;
R 8 is selected from a peptide antigen moiety or a protein antigen moiety; and
x is any integer from 1 to 10.
22. The imidazoquinoline derived compound of claim 21 , comprising a dendrimer of a compound of Formula I, wherein the compound of Formula I is the compound 1-(4-(Aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine, and wherein the dendrimer is chosen from a trimer or a hexamer of the compound.
23. The imidazoquinoline derived dendrimer compound of claim 22 , wherein the trimer of compound 7d comprises the compound 1,1′,1″-(nitrilotris(ethane-2,1-diyl))tris(3-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)thiourea), or pharmaceutically acceptable salts thereof.
24. The imidazoquinoline derived dendrimer compound of claim 22 , wherein the hexamer of compound 7d comprises the compound N 1 ,N 1 -bis(2-(di(prop-2-yn-1-yl)amino)ethyl)-N 2 ,N 2 -di(prop-2-yn-1-yl)ethane-1,2-diamine, or pharmaceutically acceptable salts thereof.
25. The imidazoquinoline derived compound of claim 21 , wherein the compound is a dimer of a compound of Formula I chosen from the following compounds: N 1 ,N 6 -bis(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)adipamide, N 1 ,N 6 -bis(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)octanediamide, N 1 ,N 12 -bis(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)dodecane diamide, or pharmaceutically acceptable salts thereof.
26. The imidazoquinoline derived compound of claim 21 , wherein the compound is a dimer of a compound of Formula II chosen from the following compounds: N 1 ,N 6 -bis(4-amino-1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-8-yl) adipamide, N 1 ,N 6 -bis(4-amino-1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-8-yl)octanediamide, N 1 ,N 12 -bis(4-amino-1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-8-yl) dodecanediamide, or pharmaceutically acceptable salts thereof.
27. The imidazoquinoline derived compound of claim 21 , wherein the dimer or dendrimer compound is a Toll-like receptor (TLR) 7 agonist or a dual TLR7/TLR8 agonist.
28. The imidazoquinoline derived compound of claim 21 , wherein the dimer or dendrimer compound is a TLR7 agonist chosen from the following compounds: 1,1′,1″-(nitrilotris(ethane-2,1-diyl))tris(3-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)thiourea), N 1 ,N 1 -bis(2-(di(prop-2-yn-1-yl)amino)ethyl)-N 2 ,N 2 -di(prop-2-yn-1-yl)ethane-1,2-diamine, N 1 ,N 6 -bis(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)adipamide, N 1 ,N 6 -bis(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)octanediamide, N 1 ,N 12 -bis(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)dodecane diamide, N 1 ,N 6 -bis(4-amino-1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-8-yl) adipamide, N 1 ,N 8 -bis(4-amino-1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-8-yl)octanediamide, N 1 ,N 12 -bis(4-amino-1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-8-yl) dodecanediamide, or pharmaceutically acceptable salts thereof.
29. The imidazoquinoline derived compound of claim 21 , wherein the dimer or dendrimer compound is a dual TLR7/TLR8 agonist chosen from compounds 1,1′,1″-(nitrilotris(ethane-2,1-diyl))tris(3-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)thiourea), N 1 ,N 12 -bis(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)dodecane diamide, or pharmaceutically acceptable salts thereof.
30. An imidazoquinoline derived compound of Formula II or pharmaceutically acceptable salt thereof, wherein
Formula II has the structure:
wherein, R 1 and R 3 are each independently selected from the group consisting of hydrogen, halogen, nitro, —NH 2 , azido, hydroxyl, —CF 3 , carboxylic acid, and —CO 2 R 2 ;
R 2 is a C 2 -C 5 alkyl, and
R 4 selected from the group consisting of: —NH(R 5 ) and isothiocyanate;
R 5 is selected from the group consisting of hydrogen, acetyl, —CO-tert-Bu (-Boc), —CO—(CH 2 ) x —R 6 , C 1 -C 16 alkyl, —CO-4-, —C(S)—NH—(CH 2 ) x —NH—(CH 2 ) x —NH—(CH 2 ) x —NH 2 ,
a reporter moiety, a tissue-specific moiety, a peptide antigen moiety, a protein antigen moiety, a polysaccharide antigen moiety, and a TLR2 agonist moiety;
R 6 is selected from the group consisting of hydrogen, alkyne, azido, carboxylic acid, and
—CONH—(CH 2 ) x —O—(CH 2 ) x —O—(CH 2 ) x —O—(CH 2 ) x —R 7 ;
R 7 is selected from the group consisting of amino, isothiocyanate, and —NH—CO—(CH 2 ) x —CO 2 H;
R 8 is selected from a peptide antigen moiety or a protein antigen moiety; and
x is any integer from 1 to 10.
31. The imidazoquinoline derived compound of claim 30 , wherein the compound is chosen from tert-butyl 3-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzylcarbamate, tert-butyl 4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzylcarbamate, 1-(3-(Aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine, 1-(4-(Aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine, 2-Butyl-1-(4-(isothiocyanatomethyl)benzyl)-1H-imidazo[4,5-c]quinolin-4-amine, 1-(4-((4-amino-2-butyl-1H-imidazo[4,5- c]quinolin-1-yl)methyl)phenyl)-3,7,23-trioxo-12,15,18-trioxa-2,8,22-triazaheptacosan-27-oic acid, 5-((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)amino)-5-oxopentanoic acid, N 1 -(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-N 5 -(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)glutaramide, N 1 -(4((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-N 5 -(3-(2-(2-(3-isothiocyanatopropoxy)ethoxy)ethoxy)propyl)glutaramide, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)palmitamide, 2-butyl-1-(4-((hexadecylamino)methyl)benzyl)-1H-imidazo[4,5-c]quinolin-4-amine, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-2-azidoacetamide, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)pent-4-ynamide , N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl) benzyl)-3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamide, (4-((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)carbamoyl)phenyl)boronic acid, 1-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-3-(3-((4(3-aminopropyl)amino)butyl)amino)propyl)thiourea, 2-(3-(4-((4-Amino-2-butyl-1H-imidazo [4,5-c]quinolin-1-yl)methyl)benzyl)thioureido)-6-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid, N-(9-(4-(3-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)thioureido)-2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene)-N-ethylethanaminium, 5-(((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)phenoxy)acetyl)amino)pentylamine, hydrochloride conjugate of 2-Butyl-1-(4-(isothiocyanatomethyl)benzyl)-1H-imidazo[4,5-c]quinolin-4-amine, Methyl 1-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)phenyl)-6,9-dioxo-3-thioxo-2,4,7,10-tetraazadodecan-12-oate,
(2R)-methyl 2-amino-5-((2S)-3-(1-(3-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinoli n-1-yl)methyl)benzylamino)-3-oxopropyl)-2,5-dioxopyrrolidin-3-ylthio)-1-(2-methoxy-2-oxoethylamino)-1-oxopropan-2-ylamino)-5-oxopentanoate,
N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-N-((2R ,3S ,4R)-2,3,4,5,6-pentahydroxyhexyl)acetamide, 5-((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl) amino)-2-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-5-oxopentanoic acid, N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide, 4-(((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)amino)methyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol
or pharmaceutically acceptable salts thereof.
32. The imidazoquinoline derived compound of claim 30 , wherein the compound is capable of activating TLR7 or dual activation of TLR7 and TLR8.
33. A vaccine adjuvant comprising an imidazoquinoline derived compound of claim 1 .
34. A self-adjuvanting vaccine comprising an imidazoquinoline derived compound of claim 1 coupled to an antigen.
35. The self-adjuvanting vaccine of claim 34 , wherein the antigen is selected from a peptide antigen, a protein antigen, or a polysaccharide antigen.
36. A method of immunizing a host comprising:
administering to the host an antigen, and
administering to the host an adjuvant comprising an imidazoquinoline derived compound of claim 1 capable of activation of TLR7 or dual activation of TLR7 and TLR8, wherein the imidazoquinoline derived compound is administered with the antigen or is coupled to the antigen.
37. A probe comprising:
a TLR7 ligand or a dual TLR7/TLR8 ligand comprising an imidazoquinoline derived compound of claim 1 , and
a reporter molecule capable of producing a detectable signal, coupled to the ligand.
38. A method of imaging activation of TLR 7, TLR 8, or both TLR7 and TLR8 comprising:
contacting a sample comprising TLR7, TLR8 or both TLR7 and TLR8 with a probe of claim 37 ; and
imaging the detectable signal produced by the reporter molecule.
39. A TLR7 antagonist comprising: an imidazoquinoline derived dimeric compound comprising a dimeric compound of Formula III, or pharmaceutically acceptable salts thereof, wherein
wherein R 1 is selected from the group consisting of hydrogen, halogen, nitro, —NH 2 , azido, hydroxyl, and —CF 3 ,
R 3 is selected from the group consisting of hydrogen and —(CH 2 ) x —NH 2 , and
x is any integer form 1 to 10.